@article{a15e0278b065461d9f4153b3ce1b3263,
title = "Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?",
abstract = "Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.",
keywords = "ATG, Grafalon, Haploidentical HSCT, Pediatrics, Sickle cell disease, Thymoglobulin",
author = "Oostenbrink, {Lisa V.E.} and {Jol-van der Zijde}, {Cornelia M.} and Jansen-Hoogendijk, {Anja M.} and Pool, {Emma S.} and {van Halteren}, {Astrid G.S.} and Moes, {Dirk Jan A.R.} and Bredius, {Robbert G.M.} and Mohseny, {Alex B.} and Smiers, {Frans J.W.} and {van Tol}, {Maarten J.D.} and Schilham, {Marco W.} and Lankester, {Arjan C.}",
note = "Publisher Copyright: {\textcopyright} 2020 King Faisal Specialist Hospital & Research Centre",
year = "2020",
month = jun,
doi = "10.1016/j.hemonc.2019.12.003",
language = "English",
volume = "13",
pages = "61--65",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",
number = "2",
}